339 related articles for article (PubMed ID: 20663870)
1. BCR-ABL but not JAK2 V617F inhibits erythropoiesis through the Ras signal by inducing p21CIP1/WAF1.
Tokunaga M; Ezoe S; Tanaka H; Satoh Y; Fukushima K; Matsui K; Shibata M; Tanimura A; Oritani K; Matsumura I; Kanakura Y
J Biol Chem; 2010 Oct; 285(41):31774-82. PubMed ID: 20663870
[TBL] [Abstract][Full Text] [Related]
2. Janus kinase 2 regulates Bcr-Abl signaling in chronic myeloid leukemia.
Samanta A; Perazzona B; Chakraborty S; Sun X; Modi H; Bhatia R; Priebe W; Arlinghaus R
Leukemia; 2011 Mar; 25(3):463-72. PubMed ID: 21183952
[TBL] [Abstract][Full Text] [Related]
3. Erythropoiesis in the absence of janus-kinase 2: BCR-ABL induces red cell formation in JAK2(-/-) hematopoietic progenitors.
Ghaffari S; Kitidis C; Fleming MD; Neubauer H; Pfeffer K; Lodish HF
Blood; 2001 Nov; 98(10):2948-57. PubMed ID: 11698276
[TBL] [Abstract][Full Text] [Related]
4. BCR-ABL oncogenic transformation of NIH 3T3 fibroblasts requires the IL-3 receptor.
Tao WJ; Lin H; Sun T; Samanta AK; Arlinghaus R
Oncogene; 2008 May; 27(22):3194-200. PubMed ID: 18071309
[TBL] [Abstract][Full Text] [Related]
5. Role of p21 RAS in p210 bcr-abl transformation of murine myeloid cells.
Mandanas RA; Leibowitz DS; Gharehbaghi K; Tauchi T; Burgess GS; Miyazawa K; Jayaram HN; Boswell HS
Blood; 1993 Sep; 82(6):1838-47. PubMed ID: 7691239
[TBL] [Abstract][Full Text] [Related]
6. BCR-ABL uncouples canonical JAK2-STAT5 signaling in chronic myeloid leukemia.
Hantschel O; Warsch W; Eckelhart E; Kaupe I; Grebien F; Wagner KU; Superti-Furga G; Sexl V
Nat Chem Biol; 2012 Jan; 8(3):285-93. PubMed ID: 22286129
[TBL] [Abstract][Full Text] [Related]
7. Jak2 is involved in c-Myc induction by Bcr-Abl.
Xie S; Lin H; Sun T; Arlinghaus RB
Oncogene; 2002 Oct; 21(47):7137-46. PubMed ID: 12370803
[TBL] [Abstract][Full Text] [Related]
8. Thrombocytosis and STAT5 activation in chronic myelogenous leukaemia are not associated with JAK2 V617F or calreticulin mutations.
Turakhia SK; Murugesan G; Cotta CV; Theil KS
J Clin Pathol; 2016 Aug; 69(8):713-9. PubMed ID: 26754830
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of the PI3K/Akt/GSK3 pathway downstream of BCR/ABL, Jak2-V617F, or FLT3-ITD downregulates DNA damage-induced Chk1 activation as well as G2/M arrest and prominently enhances induction of apoptosis.
Kurosu T; Nagao T; Wu N; Oshikawa G; Miura O
PLoS One; 2013; 8(11):e79478. PubMed ID: 24260231
[TBL] [Abstract][Full Text] [Related]
10. Bcr-Abl kinase down-regulates cyclin-dependent kinase inhibitor p27 in human and murine cell lines.
Jonuleit T; van der Kuip H; Miething C; Michels H; Hallek M; Duyster J; Aulitzky WE
Blood; 2000 Sep; 96(5):1933-9. PubMed ID: 10961897
[TBL] [Abstract][Full Text] [Related]
11. Identification of mcl-1 as a BCR/ABL-dependent target in chronic myeloid leukemia (CML): evidence for cooperative antileukemic effects of imatinib and mcl-1 antisense oligonucleotides.
Aichberger KJ; Mayerhofer M; Krauth MT; Skvara H; Florian S; Sonneck K; Akgul C; Derdak S; Pickl WF; Wacheck V; Selzer E; Monia BP; Moriggl R; Valent P; Sillaber C
Blood; 2005 Apr; 105(8):3303-11. PubMed ID: 15626746
[TBL] [Abstract][Full Text] [Related]
12. Role of p21(WAF1/CIP1) as an attenuator of both proliferative and drug-induced apoptotic signals in BCR-ABL-transformed hematopoietic cells.
Forster K; Obermeier A; Mitina O; Simon N; Warmuth M; Krause G; Hallek M
Ann Hematol; 2008 Mar; 87(3):183-93. PubMed ID: 17960378
[TBL] [Abstract][Full Text] [Related]
13. Constitutive activation of STAT5 by the BCR-ABL oncogene in chronic myelogenous leukemia.
Shuai K; Halpern J; ten Hoeve J; Rao X; Sawyers CL
Oncogene; 1996 Jul; 13(2):247-54. PubMed ID: 8710363
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of the Bcl-xL deamidation pathway in myeloproliferative disorders.
Zhao R; Follows GA; Beer PA; Scott LM; Huntly BJ; Green AR; Alexander DR
N Engl J Med; 2008 Dec; 359(26):2778-89. PubMed ID: 19109573
[TBL] [Abstract][Full Text] [Related]
15. Involvement of Jak2 tyrosine phosphorylation in Bcr-Abl transformation.
Xie S; Wang Y; Liu J; Sun T; Wilson MB; Smithgall TE; Arlinghaus RB
Oncogene; 2001 Sep; 20(43):6188-95. PubMed ID: 11593427
[TBL] [Abstract][Full Text] [Related]
16. Effects of Jak2 type 1 inhibitors NVP-BSK805 and NVP-BVB808 on Jak2 mutation-positive and Bcr-Abl-positive cell lines.
Ringel F; Kaeda J; Schwarz M; Oberender C; Grille P; Dörken B; Marque F; Manley PW; Radimerski T; le Coutre P
Acta Haematol; 2014; 132(1):75-86. PubMed ID: 24504330
[TBL] [Abstract][Full Text] [Related]
17. Mutant forms of growth factor-binding protein-2 reverse BCR-ABL-induced transformation.
Gishizky ML; Cortez D; Pendergast AM
Proc Natl Acad Sci U S A; 1995 Nov; 92(24):10889-93. PubMed ID: 7479904
[TBL] [Abstract][Full Text] [Related]
18. AHI-1 interacts with BCR-ABL and modulates BCR-ABL transforming activity and imatinib response of CML stem/progenitor cells.
Zhou LL; Zhao Y; Ringrose A; DeGeer D; Kennah E; Lin AE; Sheng G; Li XJ; Turhan A; Jiang X
J Exp Med; 2008 Oct; 205(11):2657-71. PubMed ID: 18936234
[TBL] [Abstract][Full Text] [Related]
19. The Polymorphisms in LNK Gene Correlated to the Clinical Type of Myeloproliferative Neoplasms.
Chen Y; Fang F; Hu Y; Liu Q; Bu D; Tan M; Wu L; Zhu P
PLoS One; 2016; 11(4):e0154183. PubMed ID: 27111338
[TBL] [Abstract][Full Text] [Related]
20. Janus kinase 2: a critical target in chronic myelogenous leukemia.
Samanta AK; Lin H; Sun T; Kantarjian H; Arlinghaus RB
Cancer Res; 2006 Jul; 66(13):6468-72. PubMed ID: 16818614
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
